# Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

**Authors:** Sara W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, Michał Pochopień, Maarten J. Postma, Jeanni M. T. van Loon, Jeroen H. J. Paulissen

PMC · DOI: 10.1186/s12933-025-02752-2 · Cardiovascular Diabetology · 2025-05-15

## Full-text entities

- **Diseases:** stroke (MESH:D020521), heart failure (MESH:D006333), Myocardial infarction (MESH:D009203), CKD (MESH:D012080), type 2 diabetes (MESH:D003924), CKD chronic kidney disease (MESH:D051436)
- **Chemicals:** finerenone (MESH:C576501), SoC (MESH:C001599)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12082908/full.md

---
Source: https://tomesphere.com/paper/PMC12082908